Update on Discussions & further Rule 2.10
07 April 2009 - 10:15AM
UK Regulatory
TIDMYRK
RNS Number : 2561Q
York Pharma plc
07 April 2009
York Pharma Plc
(the "Company")
&
ULURU, Inc.
("ULURU")
Update on Discussions and further Rule 2.10 announcement
On 31 March 2009, the Company announced that it was in discussions with two
potential offerors and that one of the potential offerors (the "Lender") had
entered into an agreement with the Company on 30 March 2009 to provide the
Company with a secured revolving credit facility.
The Company and ULURU today confirm that the Lender is ULURU, which is
registered in Nevada in the USA and has its headquarters in Addison, Texas.
ULURU is a specialty pharmaceutical company focused on the development of a
portfolio of wound management and oral care products to provide patients and
consumers with improved clinical outcomes through controlled delivery utilizing
its innovative NanoflexTM Aggregate technology and transmucosal delivery system.
ULURU has also signed a non-binding offer letter to acquire the Company. One of
the conditions of ULURU making any offer would be that the outstanding debt of
the Company (currently being the US$6 million of unsecured Convertible Loan
Notes 2014, together with accrued interest thereon) shall be converted into
Ordinary Shares of the Company prior to the closing of any Offer. Under the
indicated terms set out in the non-binding offer letter, the Company's
shareholders (as enlarged by the conversion of outstanding debt of the Company)
would own approximately 19.9 million ULURU common shares, representing
approximately 23% of the enlarged equity of ULURU.
Discussions between the Company and ULURU are continuing, whilst those between
the Company and the other potential offeror referred to have now been
terminated. The Board of the Company stresses that there can be no certainty
that the discussions between the Company and ULURU will lead to an offer being
made for Company.
The Company will provide a further update as and when appropriate.
For more information please contact:
+--------------------------------------+--------------------------------------+
| York Pharma Plc | Tel: +44 (0) 1908 764 020 |
| Richard Anderson, Chief Executive | |
| Officer | |
| Ian Miscampbell, Chief Financial | |
| Officer | |
| | |
+--------------------------------------+--------------------------------------+
| Collins Stewart Europe Limited | Tel: +44 (0) 207 523 8350 |
| Hugh Field / Adam Cowen | |
| | |
+--------------------------------------+--------------------------------------+
| Financial Dynamics | Tel: +44 (0) 207 831 3113 |
| Ben Brewerton / Emma Thompson | |
+--------------------------------------+--------------------------------------+
Collins Stewart Europe Limited ("Collins Stewart") which is regulated in the
United Kingdom by The Financial Services Authority is acting for the Company in
relation to the matters described in this announcement and is not advising any
other person, and accordingly will not be responsible to anyone other than the
Company for providing the protections afforded to customers of Collins Stewart
or for providing advice in relation to the matters described in this
announcement.
About York Pharma (YRK.L)
York Pharma is a pharmaceutical group, established in 2003, which develops,
markets and supplies branded dermatological products to pharmaceutical
wholesalers, hospitals and general practitioners within the field of
dermatology.
Dealing Disclosure Requirements
Under the provisions of Rule 8.3 of the City Code, if any person is, or becomes,
"interested" (directly or indirectly) in 1% or more of any class of "relevant
securities" of the Company or of the Lender, all "dealings" in any "relevant
securities" of the Company or of the Lender (including by means of an option in
respect of, or a derivative referenced to, any such "relevant securities") must
be publicly disclosed by no later than 3.30pm (London time) on the Business Day
following the date of the relevant transaction. This requirement will continue
until the offer lapses or is otherwise withdrawn or the date on which the "offer
period" otherwise ends. If two or more persons act together pursuant to an
agreement or understanding, whether formal or informal, to acquire an "interest"
in "relevant securities" of the Company, they will be deemed to be a single
person for the purpose of Rule 8.3 of the City Code.
Under the provisions of Rule 8.1 of the City Code, all "dealings" in "relevant
securities" of the Company or the Lender, or by any of their respective
"associates", must be disclosed by no later than 12.00 noon (London time) on the
Business Day following the date of the relevant transaction.
A disclosure table, giving details of the companies in whose "relevant
securities" "dealings" should be disclosed, and the number of such securities in
issue, can be found on the Panel's website at www.thetakeoverpanel.org.uk.
"Interests in securities" arise, in summary, when a person has long economic
exposure, whether conditional or absolute, to changes in the price of
securities. In particular, a person will be treated as having an "interest" by
virtue of the "ownership" or control of securities, or by virtue of any option
in respect of, or derivative referenced to, securities.
Terms in quotation marks are defined in the City Code, which can also be found
on the Panel's website. If you are in any doubt as to whether or not you are
required to disclose a "dealing" under Rule 8, you should consult the Panel.
Rule 2.10 of the City Code
In accordance with Rule 2.10 of the City Code, ULURU confirms that it has in
issue 65,582,532 shares of common stock, par value $0.001 each ("Common Stock").
The ISIN for the Common Stock of ULURU is US90403T1007.
=-oo--
This information is provided by RNS
The company news service from the London Stock Exchange
END
OFDGIGDSXBGGGCR
York Pharma (LSE:YRK)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
York Pharma (LSE:YRK)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über York Pharma (Londoner Börse): 0 Nachrichtenartikel
Weitere York Pharma plc News-Artikel